More info…
Earlier this week, King Pharmaceuticals, Inc. ( KG ) announced the launch of Embeda, which recently received U.S. Food and Drug Administration (FDA) approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda, which is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing, will be available in six dosage strengths. As per
King Launches Embeda Analyst Blog
September 25, 2009 By Leave a Comment
Speak Your Mind
You must be logged in to post a comment.